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Mycoplasma bovis can cause different systemic problems in cattle, and recently has 
been resulted in huge economic losses in China. In vitro susceptibilities of 26 twice 
sub-cultured Chinese M. bovis field isolates were determined at physiological pH 
including PG45 through broth micro-dilution method. Except Huanggang isolate, all 
isolates and PG45 were in the sensitive range for levofloxacin, lomefloxacin and 
ciprofloxacin, whereas, for norfloxacin and nalidixic acid, they had shown 
intermediate resistant and complete resistant patterns, respectively. The multiple 
sequence analysis revealed point mutations in QRDRs of gyrA and parC genes of 
Huanggang isolate resulting in amino acid substitutions at positions 83 (S-F) in 
GyrA (E. coli numbering) and 80 (S-I) in ParC proteins, the latter is reported for 
first time in M. bovis. Conclusively, fluoroquinolones are the potential veterinary 
therapeutic agents for mycoplasmosis in China and resistance to these agents comes 
through point mutations in QRDRs of gyrA and parC genes with ParC and GyrA 
mutation orientation. 
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INTRODUCTION 
 
Mycoplasma species are the smallest self-replicating 
organisms that lack cell wall. Among mycoplasma, 
mainly  Mycoplasma bovis ( M. bovis) is primarily 
involved in bovine pneumonia, mastitis, arthritis, otitis, 
meningitis, infertility and abortion leading to worldly 
massive economic losses for cattle industry (Pfützner, 
1990; Nicholas and Ayling, 2003; Arcangioli et al., 2012). 
It has also horizontal transmission ability in cattle herds 
with the highest sero-prevalence in May, June and August 
(Nicholas et al., 2008). 
The intrinsic resistance to β-lactamases, while 
acquired resistance to sulphonamides and aminogly- 
cosides had resulted in the clinical in-effectiveness of 
chemotherapy guidelines. M. bovis has also ability to 
disseminate extensively in the host that further limits their 
effective chemotherapy. Furthermore, biofilm production 
by mycoplasma may enable their survival in the host 
reducing their antimicrobial susceptibility (Kornspan et 
al., 2011). 
Due to the lull of effective available vaccine for M. 
bovis  control, its prophylaxis is exclusively reliant on 
first-rate husbandry practices and chemotherapy. 
Following  M. bovis isolation in 1961 from USA, its 
worldwide spread to many countries comes through 
animal movements. In China, M. bovis was first reported 
by this laboratory in 2008 (Lei et al., 2008). 
In vitro antimicrobial susceptibilities of M. bovis had 
already been reported from other countries (Nicholas et 
al., 2008) but nothing was reported about the Chinese M. 
bovis strains. Since China imports animals from different 
countries, so, it was quite worthy to know the 
antimicrobial susceptibilities of Chinese M. bovis isolates. 
Because quinolones were the most commonly used 
veterinary chemotherapeutic agents in China against 
mycoplasmosis and other infectious diseases, we decided 
to test their susceptibilities. We have determined the 
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minimum inhibitory concentrations (MICs) of M. bovis 
isolates and reference type strain Mycoplasma bovis 
ATCC
® 25523™ (PG45), against five quinolones through 
broth micro-dilution susceptibility method. Following 
scrutinization, quinolones-resistant determining regions 
(QRDRs) of gyrA, gyrB, parC and parE genes of these 
isolates were amplified and mutation evidence was 
measured by multiple sequence alignments (MSA) and 
phylogeny of their respective proteins.  
 
MATERIALS AND METHODS 
 
Culture of M. bovis:  M. bovis isolates (n=26) from 
different beef and dairy farms were collected from 2008 to 
2011. Isolates as M. bovis were confirmed by PCR using 
primers to uvrC gene and 16s rRNA as previously 
reported (Lei et al., 2008). The PCR products were 
custom-sequenced. Following confirmation, the isolates 
were stored at -70ºC. 
The test cultures were propagated in PPLO broth, 
supplemented with 0.5% (w/v) sodium pyruvate and 
0.09% (w/v) yeast extract, while 0.004% (w/v) phenol 
red, 1% (v/v) 10× minimum essential medium (MEM), 
20% (v/v) donor equine serum and 80,000 U of penicillin 
G/100 mL of medium after autoclavation, acquiring a 
final pH of 7.3. The measurement of color changing unit 
(ccu) was executed through viable count method for liquid 
MIC assay (Hannan, 2000). Before the conduction of 
susceptibility test for any drug, stock culture aliquots from 
each isolate were sub-cultured twice in PPLO broth (10% 
v/v) to log phase (24 h incubation, acquiring 10
9-10
10 
ccu/mL), whereas by third term log phase, susceptibility 
test was performed. The end-points were read as red to 
yellow/orange color changes in test wells. 
Testing of the PG45 had allowed a direct comparison 
between the MIC values obtained in this study and from 
previous reports (Hannan et al., 1997). To ensure the 
reproducibility and validity, PG45 was incorporated in the 
first row of each tray. MIC value of PG45 had already 
been reported for one of the presently used agent’s 
chemical analogue (Hannan, 2000). 
 
Antimicrobial agents and dilution ranges: The agents 
were nalidixic acid, ciprofloxacin, levofloxacin, 
lomefloxacin and norfloxacin. To have the comparable 
results, the un-sterilized stock solutions of 1 mg/mL were 
prepared on the antimicrobial base basis using correction 
factors (Hannan, 2000) and according to CLSI guidelines 
(Anonymous, 2010). The stock solutions were stored at -
70ºC, while the working solutions were stored at 4ºC. The 
two fold serial dilutions ranging from 128 to 0.25 µg/mL 
for nalidixic acid, 64 to 0.125 µg/mL for norfloxacin and 
16 to 0.03 µg/mL for ciprofloxacin, levofloxacin and 
lomefloxacin were used. 
 
Broth micro-dilution susceptibility method: The adhoc 
working group of international research program on 
comparative mycoplasmology (IRPCM) had proposed 
serial broth dilution method as the most useful and 
reproducible assay (Ter Laak et al., 1993). The broth 
microtiter trays’ layout was like so; columns 1 to 9 
contained 100 µL/well of broth with antimicrobial agent 
(Test wells), column 10 contained 100 µL/well of broth 
without antimicrobial agent (Growth control), columns 11 
and 12 contained 200 µL/well pH adjusted broth (pH 6.8, 
pH control) and standard broth medium (Sterility control), 
respectively. The columns from 1 to 9 were inoculated 
with 100 µL/well of ccu adjusted mycoplasma inocula 
(10
4-10
5 ccu/mL). The column 10 was inoculated with 
100 µL/well of 24 h incubated log phase broth culture 
(10
9-10
10 ccu/mL) of each clinical isolate from which ccu 
dilutions were prepared. The trays were sealed with 
adhesive tape and incubated aerobically at 37ºC. 
 
Interpretation of results:  Since there were no specific 
test guidelines regarding susceptibility analysis for 
mycoplasmas from CLSI, MICs break-points of the tested 
quinolones were based on their CLSI break-points for 
other common bacteria (Anonymous, 2010; Soehnlen et 
al., 2011). The trays were examined periodically until the 
broth color in the column No. 10 first/just matched or 
exceeded to that of the column No. 11 and MICs values at 
this change were recorded as initial MICs, which were on 
day 2 of incubation assuming the lowest concentration of 
antimicrobial agent that showed no color change when the 
color change in growth control well was equal to pH 
control well and to ensure any trailing effect of 
antimicrobial agents, final MICs, when there was no 
further color change for upto at least two days, were 
recorded on day 7 of incubation (Hannan, 2000). 
Tests were performed in duplicate pattern and 
parallely to evaluate the effect of solvents and diluent, 
separate broth samples were prepared without 
antimicrobial agent but containing the same volumes of 
solvents and diluent those had already been used. These 
taped trays were also incubated under the same conditions 
of temperature and air.  
 
Amplification of QRDRs, detection of point mutation 
and phylogeny: Genomic DNA was extracted from 1 mL 
log phase broth cultures by boiling at 100ºC for 10 min, 
followed by 1 min thawing and finally centrifugation for 
10 sec to get it in the supernatant. The sequencing was 
performed at two different DNA sequencing units, 
Sangon
® Biotech (Shanghai) Co Ltd and Beijing 
Genomics Institute
® using ABI-PRISM3730 sequencing 
reagent for Big Dye TerminatorV3.1. The translations of 
the sequence results were performed using NCBI’s DNA 
& RNA tool available at (http://www.ncbi.nlm.nih.gov 
/gorf/gorf.html). Multiple Sequence alignments of the 
isolates’ proteins were done to find out mutation evidence 
by ClustalX2.0.12 (http://www.clustal.org/). Phylogenetic 
neighbor joining (N-J) trees were also constructed by the 
same software. 
The susceptibility status of isolates for different drugs 
was statistically analyzed by T-test analysis. The isolates 
were classified as susceptible (sensitive) and non-
susceptible (intermediate and resistant) by comparison of 
the MIC to CLSI breakpoints. Differences were 
considered statistically significant when P<0.05. 
 
RESULTS 
 
Confirmation of the isolates: The isolates as M. bovis 
were confirmed by PCR through uvrC’s 238 bp Pak Vet J, 2013, 33(3): 364-369. 
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amplicons. For 16S rRNA, sequence alignment for these 
PCR products revealed 99-100% similarity.  
 
Calibration of the drug susceptibility test: These 
susceptibility results were exclusively of the quinolones 
because the trays inoculated with quinolone-free broth but 
containing the solvents and diluent as same as had 
previously been used, showed color change in all twofold 
serially diluted test wells. The validity of the currently 
executed method was assessed by the PG45, as its MIC 
value for one of the presently used fluoroquinolone, 
ciprofloxacin was 1 µg/mL that was comparable with the 
earlier report (1-2 µg/mL) using the same method 
(Hannan, 2000). 
 
Susceptibility of M. bovis isolates: In vitro susceptibility 
analysis is presented in Table 1. All isolates and PG45 
grew against the highest used concentration of nalidixic 
acid, so, isolates and PG45 were measured resistant to it. 
The isolate  with Ser. No. 4 from Huanggang, rendered 
complete resistance to all the tested quinolones and was 
excluded from susceptibility result interpretation.  
For ciprofloxacin, 96% isolates remained “Sensitive” 
while 4% were measured “Intermediate” (moderately 
sensitive). MIC value of 1 µg/mL for PG45 was also in 
the sensitive range. For levofloxacin all the isolates were 
measured “Sensitive” alongwith PG45 because according 
to author’s best of knowledge, its MIC break-points have 
yet not been standardized for this agent. For lomefloxacin, 
isolates and PG45 were measured “Sensitive”. There were 
also no MIC break-points reported for PG45 against 
lomefloxacin. For norfloxacin, 76 and 24% isolates were 
remained “Intermediate” and “Resistant” respectively. 
The PG45 was considered “Intermediate” to norfloxacin.  
 
Evidence for point mutations in QRDRs and 
phylogeny: The PCRs performed using regions specific 
primers confirmed the amplification of QRDRs by 
producing the amplicons of 531, 555, 488 and 502 bp for 
gyrA, gyrB, parC and  parE  genes,  respectively. The 
nucleotide sequences of gyrA were same in all the isolates 
except one (Huanggang). It had a single substitution of 
codon’s second nucleotide “C” at position 2381 {E. coli 
numbering, reverse complementary (RC)}, 449 (PG45 
numbering) and 2312 (M. bovis Hubei-1 and M. bovis 
HB0801 numbering, RC) by “T” resulting in amino acid 
change in GyrA protein from “S-F” at position 83 (E. coli 
numbering) and 150 (PG45, M. bovis Hubei-1 and M. 
bovis HB0801 numbering). About gyrB, no change was 
observed in QRDRs of isolates except for a non-QRDR 
transition in one isolate (Ser. No. 23); Where “G” had 
been substituted by “A” nucleotide that resulted in “G-D” 
amino acid shift at position 475 (E. coli numbering) and 
496 (PG45, M. bovis Hubei-1 and M. bovis HB0801 
numbering) in GyrB protein. This change did not affect 
the MICs of this isolate. 
Comparison of the ParC QRDRs revealed a 
substitution of an amino acid “S-I” at position 80 (E. coli 
numbering), which corresponds to position 91 (PG45, M. 
bovis Hubei-1 and M. bovis HB0801 numbering), 
resulting from the point mutation of “G-T” nucleotide at 
position 2021 (E. coli numbering), 2315 (PG45 
numbering) and 272 (M. bovis Hubei-1 and M. bovis 
HB0801 numbering) of parC. No difference was found in 
QRDRs of parE and its coordinate protein. In both QRDR 
mutations, a polar amino acid lying between acidic and 
polar amino acids, has been replaced by a non-polar 
amino acid (Table 2).  
To find out the  phylogenetic evidence for 
susceptibility  criteria  of  isolates,  phylogenetic N-J trees 
 
Table 1: Initial (day 2) and final (day 7) MICs for used quinolones 
MICs ( µg/mL ) 
NAL CIP  LVX  LOM  NOR  Isolates 
F   I
a F
b   I  F  I  F  I  F 
Yanling   >128  1  1  1  1  2  2  8  16 
Yuliang 2086   >128  0.5  1  0.5  0.5  2  2  4  8 
Jingshan 1015  >128  1  1  0.5  1  2  2  8  8 
Huanggang >128  >16  >16  >16  >  16  >16  >16  >64  >64 
NNH >128  1  1  1  1  2  2  8  16 
Yanling 0724   >128  1  1  1  1  2  2  8  8 
Yanjin 0719  >128  0.5  1  1  1  2  2  8  16 
Fangxian   >128  1  1  1  2  2  2  8  16 
Jiang xixinyu   >128  0.5  0.5  0.5  0.5  1  2  4  8 
Kaifeng   >128  0.5  0.5  1  1  1  2  8  8 
Lianjiang 1225   >128  0.5  1  1  1  1  2  8  16 
Xiamen   >128  1  1  0.5  1  1  2  4  8 
Xiantao   >128  2  2  1  2  2  2  8  8 
Suizhou   >128  1  1  1  1  1  2  4  8 
Xinzhou-2   >128  0.5  1  1  1  2  2  8  8 
Xinzhou-1   >128  1  1  0.5  1  2  2  8  16 
Yingcheng HB0801 >128  1  1  1  1 2 2 8 8 
Zhongxiang >128  0.25  0.5  0.5  1  1  2  4  8 
Ezhou-8   >128  0.25  0.5  0.5  1  1  2  8  8 
Daye   >128  1  1  1  1  1  2  4  8 
Ezhou-3   >128  0.5  1  0.5  1  1  2  4  8 
Bozhou   >128  0.5  1  1  1  1  2  8  8 
Ezhou-2   >128  1  1  1  1  2  2  4  8 
Zhuma dian   >128  1  1  1  1  1  2  4  8 
LLLQ >128  1  1  1  1  1  2  4  8 
Ezhou >128  0.5  1  1  1  2  2  8  8 
PG45 >128  1  1  0.5  1  1  2  8  8 
Notes: 
aInitial; 
bFinal; Nalidixic Acid (NAL); Ciprofloxacin (CIP); Levofloxacin (LVX); Lomefloxacin (LOM) and Norfloxacin (NOR); According to T-
test statistical analysis, the isolates from all the provinces were sensitive to all the drugs except nalidixic acid. Pak Vet J, 2013, 33(3): 364-369. 
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Fig. 1:   MSA and Phylogeny for GyrA and GyrB of M. bovis isolates and PG45. *numbers on the left side are isolates Ser. No. 
 
were constructed for proteins (Fig. 1  and 2). From results, 
it was obvious that resistant isolate did not fall in any of the 
four main clusters of GyrA. The analysis of phylogenetic 
tree for ParC pointed out that all the isolates those gave 
intermediate susceptibilities to norfloxacin fall in cluster E, 
except the isolates with Ser. No. 5 and 1. There was no 
information from GyrB and ParE phylogeny, harboring no 
change in QRDRs of isolates. Statistically no influence of 
geographic origin of isolates on susceptibility status was 
observed but there was significant difference among 
susceptible and non-susceptible isolates for all the used 
drugs from all the provinces.  
 
DISCUSSION 
 
  Our study has obviously oriented the inevitability for 
periodic quinolones susceptibility testing as the source for 
coherent chemotherapy against bovine mycoplasmosis that 
is responsible for huge economic losses due to the non-
provision of effective vaccine. This research work has also 
produced the first in vitro susceptibility report for Chinese 
M. bovis strains against quinolones. Two of the China’s 
isolated M. bovis strains (Hubei-1 and HB0801) from same 
province have been completely sequenced (Li et al., 2011; 
Qi et al., 2012); the later has been used in our study (Table 
1, Ser. No. 17). The replicate’s results were accepted when 
they were identical or differ by a single two fold serial 
dilution between initial and final MICs (Qaiyumi, 2007). 
 
Table 2:  Most common position of QRDRs proteins transition in 
mycoplasmas 
GyrA ParC  Reference Species 
83* 80 
Current study  M. bovis Huanggang isolate  S-F S-I 
Lysnyansky et al. (2009) M. bovis  S-F - 
Gruson et al. (2005)   M. hominis  S-L S-I 
Bébéar et al. (1998)   M. hominis PG21  S-L/W S-I 
Li et al. (2012)   M. gallisepticum  S-I S-L 
Reinhardt et al. (2002)  M. gallisepticum MG ATCC15302  S-R S-L 
Shimada et al. (2010)   M. ganitalium  - S-N 
Vicca et al. (2007)   M. hyopneumoniae  A-V S-Y 
Hirose et al. (2004)  M. bovirhinis   - S-L 
 
N-J Tree showing 4 main clusters  N-J Tree showing 7 main clusters Pak Vet J, 2013, 33(3): 364-369. 
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Fig. 2:  MSA and Phylogeny for ParC of M. bovis isolates and PG45 
 
We had read the final MICs after 7 days to seek out 
any trailing effect of these bactericidal agents by re-
incubating the trays after taking initial MICs on day 2. But 
the other authors read these after 2-3, 3, 4, 5, 6 or 7 days, 
except Hannan (2000) who had taken the final MIC values 
after day 7 and also yielded the MIC value for PG45, none 
of others had reported the MICs values of PG45 against 
any of the presently used quinolones. 
The antimicrobial susceptibilities were obtained at 
physiological pH of 7.3 in this study to reflect 
physiological conditions rather than usually used 7.6-7.8. 
Thus, the in vitro results were obtained at in vivo 
condition of pH, which might be clinically more 
applicable and accurate. 
The practice of using a frozen culture of a previously 
determined titer as an inoculum was having pitfalls like 
loss of viability during storage or thawing. Even if this 
does not occur, the lag phase of thawed cultures is likely 
to be prolonged over that of a fresh culture and MICs 
could be falsely elevated. To eliminate such factors along 
with the effect of cryoprotectant, the isolates were sub-
cultured to log phase twice and by third sub-culturing, 
susceptibility test was performed. The sub-culturing with 
10% v/v was done as larger sampling volume provides a 
greater number of colonies, enhancing the test precision 
(Donna et al., 1999). 
The MIC50s and MIC90s values of lomefloxacin for 
Chinese M. bovis differ from corresponding values of M. 
pneumoniae and M. hominis. For Chinese M. bovis, they 
were same i.e. 2 µg/mL but for M. pneumoniae and M. 
hominis, they were within accepted difference of single 
two fold dilution (Renaudin and Bébéar, 1990). 
The Huanggang isolate mutation in GyrA at position 
83 (S-F) was the most common coordinate for amino acid 
transition in mycoplasma. Above all, the ParC mutation in 
Huanggang isolate at position 80 (S-I) is reported for first 
time for M. bovis strain in this study, although this 
mutation had been reported in other species of genus 
mycoplasma. In M. hyopneumoniae, mutation at the same 
coordinate  gave low-level resistance, while ParC and 
GyrA mutation combination resulted in high-level 
resistance. For M. bovis, mutation in GyrA was 
considered to be responsible for intermediate resistance 
(Lysnyansky  et al., 2009). But the N-J tree for GyrA 
protein of Chinese isolates did not provide any 
phylogenetic evidence for this consideration, rather it 
showed that the intermediate resistant isolates were falling 
in different cluster and none of them was accompanying 
resistant Huanggang isolate. On the other hand, if we 
analyze the N-J tree for ParC, it was quite realistic and 
also followed the target specificity like other 
mycoplasmas, that all the intermediate resistant isolates 
were in one cluster except 2 isolates (Ser. No. 1 and 5). 
Isolate No. 5 was the closest neighbor to this cluster, 
while isolate No. 1 was lying in the same cluster that for 
Huanggang isolate. Except for a silent mutation in non-
QRDR, no transition was observed in GyrB, which was in 
apposition to M. hominis,  M. hyopneumoniae,  U. 
urealyticum and  A. laidlawii but in opposition to M. 
gallisepticum. No mutation was seen in ParE as for M. 
hyopneumoniae and M. hominis, whereas M. 
gallisepticum has mutation in this protein (Carrou et al., 
2006).  
In China, use of quinolone drugs is very common 
which is even indicated from very high rate of their 
resistance, reaching even upto 100% in some areas (Wang 
et al., 2006). This is also positively supported from our 
study, where Huanggang isolate has shown resistance to 
all of the tested quinolones. Furthermore, this is an 
alarming indication that the number of resistant isolates is 
increasing as evident from M. bovis isolates’ and PG45’s 
resistances to nalidixic acid, norfloxacin and ciprofloxacin 
in different amplitudes. 
 
Conclusion: The broth micro-dilution susceptibility 
method has been successfully executed for the 
determination of quinolones MICs against M. bovis field 
isolates and PG45. Huanggang isolate remained resistant/ 
mutant through broth micro-dilution method, sequencing 
of QRDRs of gyrA and parC genes and phylogeny. These 
N-J Tree showing 5 main clusters Pak Vet J, 2013, 33(3): 364-369. 
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facts also provide the authenticity to our designed 
susceptibility methodology. Levofloxacin, lomefloxacin 
and ciprofloxacin remained the most effective in vitro 
fluoroquinolones for mycoplasmosis. The development of 
resistance to quinolones was related to point mutations in 
QRDRs of target genes following the mutation trend from 
ParC to GyrA.  
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